Pegaptanib sodium for the treatment of age-related macular degeneration

Author: Apte, Rajendra S

Source: Expert Opinion on Pharmacotherapy, Volume 9, Number 3, February 2008 , pp. 499-508(10)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Background: Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeability. Objective: To briefly present the pharmacology, clinical efficacy and safety, and role of pegaptanib in treating ocular neovascular diseases. Methods: A systematic literature review and synopsis. Results/conclusion: After more than 10 years in development, clinical trials have shown pegaptanib efficacy in treating choroidal neovascularization of age-related macular degeneration. Its excellent ocular and systemic safety profiles have been confirmed in up to 3 years of experience. Early phase, well-controlled studies also suggest therapeutic benefit in diabetic retinopathy and retinal vein occlusion.

Keywords: age-related macular degeneration; aptamer; choroidal neovascularization; pegaptanib; vascular endothelial growth factor

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14656566.9.3.499

Affiliations: 1: Assistant Professor St Louis School of Medicine Washington University, Department of Ophthalmology & Visual Sciences, Barnes Retina Institute, 660 S. Euclid Avenue, PO Box 8096, St Louis, MO 63110, USA +1 314 367 1181; +1 314 362 6793;, Email: Apte@vision.wustl.edu

Publication date: 2008-02-01

More about this publication?